Omalizumab for management of hypersensitivity reactions to anticancer drugs-Reference-Cited by-同舟云学术

Omalizumab for management of hypersensitivity reactions to anticancer drugs

Published:2024-07-19 Issue:8 Volume:54 Page:1396-1400
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Internal Medicine Journal

Author:

Grover Piyush¹²³^ORCID,Krummenacher Matthew¹,Loy Timothy¹,Nowak Anna K.²,Lucas Michaela¹²⁴⁵

Affiliation:

1. Department of Immunology Sir Charles Gairdner Hospital Perth Western Australia Australia

2. Medical School, The University of Western Australia Perth Western Australia Australia

3. Department of Medical Oncology Fiona Stanley Hospital Perth Western Australia Australia

4. Department of Immunology Perth Children's Hospital Perth Western Australia Australia

5. PathWest Perth Western Australia Australia

Abstract

AbstractHypersensitivity reactions to anticancer drugs include treatment‐limiting toxicity. Standard drug desensitisation offers temporary tolerance and hence requires repetition. We used omalizumab, an anti‐immunoglobulin E antibody, to overcome immediate and delayed hypersensitivity reactions to various anticancer drugs. Seven of the eight patients in the current study successfully resumed the desired anticancer drug regimen without standard desensitisation. No safety issues from omalizumab were observed.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imj.16464

Reference21 articles.

1. Cancer statistics, 2023

2. Readministration of Platinum Agents in Recurrent Ovarian Cancer Patients Who Developed Hypersensitivity Reactions to Carboplatin

3. Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs

4. Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases

5. Does Rapid Drug Desensitization to Chemotherapy Affect Survival Outcomes?